Archimedes Pharma wins the Scrip Award for SME Pharma Company of the Year
Archimedes won for a number of reasons. The Company’s lead development product is NasalFent, an fentanyl citrate nasal spray, for the rapid release of breakthrough cancer pain, based on Archimedes’ PecSys™ technology. Archimedes has completed a full phase III programme for NasalFent. The judges were impressed with the filing of a regulatory dossier with EMEA and a US NDA filing in September, all against the backdrop of establishing a profitable, growing, commercial company.
Richard de Souza, CEO of Archimedes Pharma, said: “2009 has been a tough year for the life sciences sector, but against this backdrop we have worked extremely hard to meet key milestones for the company and its shareholders. It is extremely rewarding to see this recognised by Scrip and we look towards 2010 with great confidence.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.